WO2002086084A3 - Sequence characteristics of bladder cancer - Google Patents

Sequence characteristics of bladder cancer Download PDF

Info

Publication number
WO2002086084A3
WO2002086084A3 PCT/US2002/012774 US0212774W WO02086084A3 WO 2002086084 A3 WO2002086084 A3 WO 2002086084A3 US 0212774 W US0212774 W US 0212774W WO 02086084 A3 WO02086084 A3 WO 02086084A3
Authority
WO
WIPO (PCT)
Prior art keywords
bladder cancer
expressed gene
indicative
patient
sequence characteristics
Prior art date
Application number
PCT/US2002/012774
Other languages
French (fr)
Other versions
WO2002086084A2 (en
WO2002086084B1 (en
Inventor
Elena Feinstein
Orna Mor
Original Assignee
Quark Biotech Inc
Elena Feinstein
Orna Mor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/825,682 external-priority patent/US6998232B1/en
Application filed by Quark Biotech Inc, Elena Feinstein, Orna Mor filed Critical Quark Biotech Inc
Priority to AU2002338431A priority Critical patent/AU2002338431A1/en
Publication of WO2002086084A2 publication Critical patent/WO2002086084A2/en
Publication of WO2002086084A3 publication Critical patent/WO2002086084A3/en
Publication of WO2002086084B1 publication Critical patent/WO2002086084B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering a patient a therapeutically effective amount of chemical compound are also provided.
PCT/US2002/012774 2001-04-04 2002-04-04 Sequence characteristics of bladder cancer WO2002086084A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002338431A AU2002338431A1 (en) 2001-04-04 2002-04-04 Sequence characteristics of bladder cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/825,682 US6998232B1 (en) 1999-09-27 2001-04-04 Methods of diagnosing bladder cancer
US09/825,682 2001-04-04

Publications (3)

Publication Number Publication Date
WO2002086084A2 WO2002086084A2 (en) 2002-10-31
WO2002086084A3 true WO2002086084A3 (en) 2003-03-27
WO2002086084B1 WO2002086084B1 (en) 2003-11-20

Family

ID=25244665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/012774 WO2002086084A2 (en) 2001-04-04 2002-04-04 Sequence characteristics of bladder cancer

Country Status (2)

Country Link
AU (1) AU2002338431A1 (en)
WO (1) WO2002086084A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
DE10309729A1 (en) * 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Human nucleic acid sequences from bladder cancer
ES2612482T3 (en) 2004-07-23 2017-05-17 Pacific Edge Limited Urine markers for bladder cancer detection
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
KR102504750B1 (en) 2010-09-29 2023-03-02 어젠시스 인코포레이티드 Antibody drug conjugates (adc) that bind to 191p4d12 proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422243A (en) * 1991-01-15 1995-06-06 Jalkanen; Markku T. Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells
US6207380B1 (en) * 1997-09-15 2001-03-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
WO2001022864A2 (en) * 1999-09-27 2001-04-05 Quark Biotech, Inc. Sequences characteristic of bladder cancer
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422243A (en) * 1991-01-15 1995-06-06 Jalkanen; Markku T. Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells
US6207380B1 (en) * 1997-09-15 2001-03-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
WO2001022864A2 (en) * 1999-09-27 2001-04-05 Quark Biotech, Inc. Sequences characteristic of bladder cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 15 February 2000 (2000-02-15), ROSENTHAL ET AL.: "Human bladder tumour cDNA library derived EST 15", XP002958549, Database accession no. (AAZ24403) *
DATABASE GENBANK [online] BILLING-MEDEL ET AL.: "Sequence 7 from patent", XP002958548, accession no. EMBL Database accession no. (AR139477) *
DATABASE GENBANK [online] February 2002 (2002-02-01), "Homo sapiens cDNA clone", XP002958550, accession no. EST Database accession no. (BG291376) *
DATABASE GENBANK [online] QUARK BIOTECH. INC.; July 2001 (2001-07-01), "Bladder cancer-associated sequence, TCC94G3", XP002958552, Database accession no. (AAS01297) *
DATABASE GENBANK [online] QUARK BIOTECHN. INC.; July 2001 (2001-07-01), "Bladder cancer-associated sequence, TCC75E3", XP002958551, Database accession no. (AAS01308) *

Also Published As

Publication number Publication date
AU2002338431A1 (en) 2002-11-05
WO2002086084A2 (en) 2002-10-31
WO2002086084B1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
EP2258872A3 (en) Gene expression profiling in biopsied tumor tissues
WO2003042661A8 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
HK1148783A1 (en) Gene expression markers for breast cancer prognosis
AU2003260966A1 (en) Genes and polypeptides relating to human pancreatic cancers
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2003065006A3 (en) Methods and compositions for treating cancer
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2002061144A8 (en) Brain tumor diagnosis and outcome prediction
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
DE60137264D1 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO2002086084A3 (en) Sequence characteristics of bladder cancer
MXPA05014220A (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets.
WO2002092858A3 (en) Methods of screening for disease
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2004109286A3 (en) Methods for detecting and treating cancer using podocalyxin and/or endoglycan
WO2002064023A3 (en) Fra-1 expression in brain cancer
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
WO2001098359A3 (en) Cyr61 as a target for treatment and diagnosis of breast cancer
WO2005017183A3 (en) Methylated gene biomarkers for detecting cancer
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Free format text: 20030227

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP